Digital RESI Pitch Session
Dermadiagnostics is developing a noninvasive, wearable patch that allows patients to appropriately test for high-risk biomarkers leading to the rise of malignant gynecologic cancer health. To date, within the United States, about 39M women are affected by the human papilloma (HPV), the main cause of cervical cancer (CDC). Currently, the available tests on the market have advanced specificity but fail to have high sesitivity. Although there have been major advancements in diagnostics for rapid detection of samples; there still is no immediate option for screening, diagnosting, and monitoring noninvasively. dermadiagnostics patent-pending molecular diagnostic is noninvasive and able to detect high-risk HPV-associated and pre-cancerous cervical inraepithelial neoplasia (CIN II and CIN III) biomarkers.